ValuEngine upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a buy rating in a research report released on Wednesday morning.

Several other equities research analysts have also weighed in on SUPN. BidaskClub lowered Supernus Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, May 24th. Stifel Nicolaus raised their price objective on Supernus Pharmaceuticals from $50.00 to $60.00 and gave the stock a buy rating in a research note on Friday, May 25th. Piper Jaffray Companies set a $47.00 price objective on Supernus Pharmaceuticals and gave the stock a hold rating in a research note on Monday, July 2nd. Zacks Investment Research lowered Supernus Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, August 1st. Finally, Cantor Fitzgerald set a $56.00 price objective on Supernus Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $54.67.

SUPN opened at $48.90 on Wednesday. The firm has a market cap of $2.55 billion, a PE ratio of 27.32 and a beta of 0.83. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.74 and a quick ratio of 2.54. Supernus Pharmaceuticals has a fifty-two week low of $33.30 and a fifty-two week high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.14. The business had revenue of $99.54 million during the quarter, compared to analyst estimates of $101.01 million. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. equities research analysts forecast that Supernus Pharmaceuticals will post 1.97 earnings per share for the current fiscal year.

In other news, VP Padmanabh P. Bhatt sold 7,795 shares of the firm’s stock in a transaction on Friday, June 29th. The stock was sold at an average price of $59.92, for a total value of $467,076.40. Following the completion of the sale, the vice president now owns 7,795 shares of the company’s stock, valued at $467,076.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Gregory S. Patrick sold 35,000 shares of the firm’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $56.63, for a total value of $1,982,050.00. Following the completion of the sale, the chief financial officer now directly owns 75,975 shares of the company’s stock, valued at approximately $4,302,464.25. The disclosure for this sale can be found here. Company insiders own 6.20% of the company’s stock.

Several institutional investors have recently modified their holdings of SUPN. SevenBridge Financial Group LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $113,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $203,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $204,000. Everence Capital Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $205,000. Finally, Cim LLC purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $207,000. 97.45% of the stock is owned by institutional investors and hedge funds.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: Determine Your Level of Risk Tolerance

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.